RT Journal Article SR Electronic T1 Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP PA3735 DO 10.1183/13993003.congress-2021.PA3735 VO 58 IS suppl 65 A1 Francesco Menzella A1 Maria Aliani A1 Elena Altieri A1 Pietro Bracciale A1 Stefano Centanni A1 Fausto De Michele A1 Fabiano Di Marco A1 Girolamo Pelaia A1 Micaela Romagnoli A1 Pietro Schino A1 Silvia Boarino A1 Gianfranco Vitiello A1 Paola Rogliani YR 2021 UL http://erj.ersjournals.com/content/58/suppl_65/PA3735.abstract AB Background: Safety and efficacy of benralizumab (BEN) for severe eosinophilic asthma (SEA) have been demonstrated in Phase III clinical trials. Obesity is a risk factor for SEA and might affect the beneficial effect of asthma medication. ANANKE is part of AstraZeneca’s global XALOC real-world evidence program for benralizumab.Aims: To explore whether benralizumab efficacy is affected by body mass index (BMI) in SEA patients.Methods: Post-hoc analysis of an observational, multicenter, retrospective Italian study of SEA patients with at least 12 weeks of BEN treatment. Patients were stratified according to BMI: normal/underweight (Nr) (BMI<25), overweight (OW) (BMI 25-29) and obese (Ob) (BMI≥30). Clinical features, asthma control (ACT) and annualized exacerbation rates (AER) reported in the three groups before and after BEN administration.Results: 182 patients were included, Nr=70 (68.6% female, mean age 55±12.8, median BEN duration 9.2 months), OW=79 (48.1% female, mean age 56.6±12.9, median BEN duration 9.4 months), Ob=33 (75.8% female, mean age 56.5±14.7, median BEN duration 10.2 months). Any AER passed from 4.49 to 0.18 (-96%) in Nr (N=66), from 3.99 to 0.32 (-92%) in OW (N=76) and from 3.72 to 0.34 (-90.9%) in Ob (N=30). Severe AER changed from 1.32 to 0.04 (-97%) in Nr, from 1.12 to 0.10 (-91.1%) in OW and from 1.13 to 0.08 (-92.9%) in Ob. ACT increased from a median of 15 in Nr (N=57), 14 in OW (N=61) and 13 in Ob (N=25) to 22 in Nr (N=29) and Ob (N=11) and 23 in Ow (N=35) at week 48.Conclusions: In an Italian real-world setting, the efficacy of BEN in SEA patients seems not to be affected by obesity, leading to asthma control al >90% reduction of AER and severe AER regardless of BMI.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3735.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).